Bulk Paclitaxel - A Global Update of Market Trends & Opportunities

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.INDUSTRY OVERVIEW
Paclitaxel – Leading from the Front
US Market – Magnificently Outdistancing Others
Cancer Blockbusters – Facing the Brunt
A Sunrise Opportunity
BMS’ Reign Comes to an End
Exploring New Avenues
Falling Prices – Boon for The Customers, Bane for The Companies
All the Strangle for Peanuts?
Factors Affecting the Market
Paclitaxel Versus Abraxane
3.OUTLOOK
Competitive Scenario
Cancer Generics – A Time for Optimism
The US Piazza
4.PRODUCT FACTS
5.RESEARCH AND DEVELOPMENT
Angiotech Unfurls New Dimensions for Paclitaxel
Clinical Research Favors Paclitaxel for Breast Cancer Treatment
American BioScience’ Nab Technology Unveils Higher Tissue Penetration Potential
Naturol Develops Unique Extraction Technology for Producing Paclitaxel from Canadian Yew
Ivax Corp.’s Xorane Revolutionizes the Delivery of Paclitaxel
6.CORPORATE DEVELOPMENTS
Sonus to Merge with OncoGenex
Acusphere Signs Licensing Deal with Cephalon
Sonus Terminates TOCOSOL Paclitaxel Development Program
Eagle Pharmaceuticals to Develop and Market Tocosol Paclitaxel
Pliva Lachema Receives ANDA for Paclitaxel Injection
Cell Therapeutics Receives EMEA Acceptance
Abraxis Wins Approval for ABRAXANE in Korea
Boston Scientific Obtains Approval for TAXUS® Liberte® from Health Canada
Cell Therapeutics Renames Xyotax as Opaxio
Dabur Launches Cancer Drug
Hospira Takes Over Mayne Pharma
Protherics to Acquire MacroMed
Abraxis Acquires Arizona Production Facility
Indena Inks Worldwide License Agreement with Spectrum Pharma
Bioxel Bags Major Paclitaxel Order
Bioxel Enters into Supply Agreement
Bioxel Bags Paclitaxel Supply Contract
Indena Establishes New Plant to Produce Synthetic Paclitaxel
Abraxis Selects Korean Green Cross to Market ABRAXANE®
Abraxis Grants License to Biocon for Marketing ABRAXANE®
Bioxel Registers Docetaxel with US FDA
Bayer Quashes TOCOSOL Paclitaxel License with Sonus
Abraxis’ ABRAXANE Convinces European CHMP
Abraxis Receives Approval for ABRAXANE in Australia
Eurocor Receives CE Mark
SuperGen Divests Certain Drugs to Intas
Abraxis Plans Separation of Oncology Business
Dabur Introduces Nanoxel
7.MAJOR PLAYERS
Abraxis BioScience, Inc. (USA)
Bristol-Myers Squibb Co. (USA)
Hospira, Inc. (USA)
Indena S.p.A. (Italy)
OncoGenex Pharmaceuticals, Inc. (USA)
Teva Pharmaceuticals USA, Inc. (USA)
8.MARKET ANALYTICS
9.THE UNITED STATES
Rising Demand for Paclitaxel
Alarming Growth of Breast Cancer
Clinical Research Favors Paclitaxel for Breast Cancer Treatment
Paclitaxel – An Important Element
Corporate Talk
Drug-Eluting Stents – Marching Ahead
10.REST OF WORLD
Europe
European Market Overview
European Market Battling Cost- Containment Woes
Efforts to Improve the Scenario and their Effect on Paclitaxel Market
China
Chinese Government Strategizing to Save Paclitaxel Reserves
Exhibits
Table 1: Global Bulk Paclitaxel Market by Region for the Period 2007-2015 (Sales in Kilograms)
Table 2: Percentage Breakdown (Volume Sales) of Global Bulk Paclitaxel Market by Region for the Years 2008 & 2009
Table 3: Global Bulk Paclitaxel Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 4: Percentage Breakdown (Dollar Sales) of Global Bulk Paclitaxel Market by Region for the Years 2008 & 2009
Table 5: Bulk Paclitaxel Market in the US: 2007-2015 (Sales in Kilograms)
Table 6: Bulk Paclitaxel Market in the US: 2007-2015 (Sales in US$ Million)
Table 7: Bulk Paclitaxel Market in Rest of World: 2007-2015 (Sales in Kilograms)
Table 8: Bulk Paclitaxel Market in Rest of World: 2007-2015 (Sales in US$ Million)Companies Profiled